Cover Image
市場調查報告書

黑色素瘤:開發平台分析

Melanoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232839
出版日期 內容資訊 英文 1656 Pages
訂單完成後即時交付
價格
Back to Top
黑色素瘤:開發平台分析 Melanoma - Pipeline Review, H2 2016
出版日期: 2016年12月28日 內容資訊: 英文 1656 Pages
簡介

所謂黑色素瘤,是黑色素細胞惡性轉換發展成腫瘤。這些細胞是來自神經嵴,黑色素瘤通常出現在皮膚上,不過是在神經嵴移行的地方譬如消化管和腦發生。女性比男性好發,尤其出現在女性的腳和男性的背部。皮膚上如果有是黑痣,痛的地方、塊、傷、花樣等明顯看到或感覺到的地方為黑色素瘤的前兆。治療方法有手術和放射線及質子治療等。

本報告提供黑色素瘤的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關開發中的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 黑色素瘤 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8868IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2016, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 92, 111, 3, 208, 24 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 14, 10, 62 and 12 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Melanoma Overview
  • Therapeutics Development
  • Melanoma - Therapeutics under Development by Companies
  • Melanoma - Therapeutics under Investigation by Universities/Institutes
  • Melanoma - Pipeline Products Glance
  • Melanoma - Products under Development by Companies
  • Melanoma - Products under Investigation by Universities/Institutes
  • Melanoma - Companies Involved in Therapeutics Development
  • Melanoma - Therapeutics Assessment
  • Drug Profiles
  • Melanoma - Dormant Projects
  • Melanoma - Discontinued Products
  • Melanoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Melanoma, H2 2016
  • Number of Products under Development for Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Development by Companies, H2 2016 (Contd..19)
  • Number of Products under Development by Companies, H2 2016 (Contd..20)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
  • Melanoma - Pipeline by 4SC AG, H2 2016
  • Melanoma - Pipeline by AB Science SA, H2 2016
  • Melanoma - Pipeline by AbbVie Inc, H2 2016
  • Melanoma - Pipeline by Abivax SA, H2 2016
  • Melanoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by Adamis Pharmaceuticals Corp, H2 2016
  • Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Melanoma - Pipeline by Adicet Bio Inc, H2 2016
  • Melanoma - Pipeline by Aduro BioTech Inc, H2 2016
  • Melanoma - Pipeline by Advanced Cancer Therapeutics, H2 2016
  • Melanoma - Pipeline by Advaxis Inc, H2 2016
  • Melanoma - Pipeline by Aeterna Zentaris Inc, H2 2016
  • Melanoma - Pipeline by Affichem SA, H2 2016
  • Melanoma - Pipeline by Agalimmune Ltd, H2 2016
  • Melanoma - Pipeline by Agenus Inc, H2 2016
  • Melanoma - Pipeline by Agilvax Inc, H2 2016
  • Melanoma - Pipeline by AGV Discovery SAS, H2 2016
  • Melanoma - Pipeline by AIMM Therapeutics BV, H2 2016
  • Melanoma - Pipeline by Alethia Biotherapeutics Inc, H2 2016
  • Melanoma - Pipeline by Altor BioScience Corp, H2 2016
  • Melanoma - Pipeline by Amgen Inc, H2 2016
  • Melanoma - Pipeline by Anavex Life Sciences Corp, H2 2016
  • Melanoma - Pipeline by Angimmune LLC, H2 2016
  • Melanoma - Pipeline by Antibe Therapeutics Inc, H2 2016
  • Melanoma - Pipeline by Antigen Express Inc, H2 2016
  • Melanoma - Pipeline by APEIRON Biologics AG, H2 2016
  • Melanoma - Pipeline by Apexigen Inc, H2 2016
  • Melanoma - Pipeline by Aphios Corp, H2 2016
  • Melanoma - Pipeline by APO-T BV, H2 2016
  • Melanoma - Pipeline by Apogenix GmbH, H2 2016
  • Melanoma - Pipeline by Aposense Ltd, H2 2016
  • Melanoma - Pipeline by Aptose Biosciences Inc, H2 2016
  • Melanoma - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by ARMO Biosciences Inc, H2 2016
  • Melanoma - Pipeline by Array BioPharma Inc, H2 2016
  • Melanoma - Pipeline by Asana BioSciences LLC, H2 2016
  • Melanoma - Pipeline by Astellas Pharma Inc, H2 2016
  • Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by AstraZeneca Plc, H2 2016
  • Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
  • Melanoma - Pipeline by Azaya Therapeutics Inc, H2 2016
  • Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
  • Melanoma - Pipeline by Batu Biologics Inc, H2 2016
  • Melanoma - Pipeline by Bayer AG, H2 2016
  • Melanoma - Pipeline by BeiGene Ltd, H2 2016
  • Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016
  • Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by BerGenBio AS, H2 2016
  • Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
  • Melanoma - Pipeline by Biocad, H2 2016
  • Melanoma - Pipeline by Biogazelle NV, H2 2016
  • Melanoma - Pipeline by Biogenomics Ltd, H2 2016
  • Melanoma - Pipeline by BioLineRx Ltd, H2 2016
  • Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016
  • Melanoma - Pipeline by Bionomics Ltd, H2 2016
  • Melanoma - Pipeline by BioNTech AG, H2 2016
  • Melanoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016
  • Melanoma - Pipeline by Biovista Inc, H2 2016
  • Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Melanoma - Pipeline by Boston Biomedical Inc, H2 2016
  • Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Melanoma - Pipeline by Calithera Biosciences Inc, H2 2016
  • Melanoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016
  • Melanoma - Pipeline by CCRP Therapeutics GmbH, H2 2016
  • Melanoma - Pipeline by Cellceutix Corp, H2 2016
  • Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Melanoma - Pipeline by Celprogen Inc, H2 2016
  • Melanoma - Pipeline by Celyad SA, H2 2016
  • Melanoma - Pipeline by Checkmate Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Melanoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
  • Melanoma - Pipeline by Cipher Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by Cortice Biosciences Inc, H2 2016
  • Melanoma - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by CytomX Therapeutics Inc, H2 2016
  • Melanoma - Pipeline by Cytune Pharma SAS, H2 2016
  • Melanoma - Pipeline by CyTuVax BV, H2 2016
  • Melanoma - Pipeline by CZ BioMed Corp, H2 2016
  • Melanoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Melanoma - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
  • Melanoma - Pipeline by DEKK-TEC Inc, H2 2016
  • Melanoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
  • Melanoma - Pipeline by DormaTarg Inc, H2 2016
  • Melanoma - Pipeline by Dynavax Technologies Corp, H2 2016
  • Melanoma - Pipeline by Eisai Co Ltd, H2 2016
  • Melanoma - Pipeline by Eli Lilly and Company, H2 2016
  • Melanoma - Pipeline by Elsalys Biotech SAS, H2 2016
  • Melanoma - Pipeline by Ensol Biosciences Inc, H2 2016
  • Melanoma - Pipeline by EntreChem SL, H2 2016
  • Melanoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016
  • Melanoma - Pipeline by Evelo Therapeutics Inc, H2 2016
  • Melanoma - Pipeline by Exelixis Inc, H2 2016
  • Melanoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Melanoma - Pipeline by Faes Farma SA, H2 2016
  • Melanoma - Pipeline by Five Prime Therapeutics Inc, H2 2016
  • Melanoma - Pipeline by Formune SL, H2 2016
  • Melanoma - Pipeline by Galapagos NV, H2 2016
  • Melanoma - Pipeline by Galectin Therapeutics Inc, H2 2016
  • Melanoma - Pipeline by Genelux Corp, H2 2016
  • Melanoma - Pipeline by Genocea Biosciences Inc, H2 2016
  • Melanoma - Pipeline by Genzyme Corp, H2 2016
  • Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016

List of Figures

  • Number of Products under Development for Melanoma, H2 2016
  • Number of Products under Development for Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top